InsidersTradesSigma
Follow the Petmed Express INC stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Petmed Express INC has logged 80 reports. Market capitalisation: €42.1m. The latest transaction was disclosed on 13 August 2026 (Attribution). Among the most active insiders: NINA CAPITAL HOLDINGS INC.. The full history is free.
80
Insider Decl.
n/a
Thresholds
€3m
23 ops.
Buy Volume
€382,672
8 ops.
Sell Volume
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,576 of 29,055 companies
8.8
score / 100
Value1
Quality16
FCF yld-81%
Earn yld-141%
EV/EBITDA·
ROE-79%
Gross mgn28%
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 August 2026
Declarations80 total
60,000 shares0Common StockSEC:0001686078-26-000004:0
55,555 shares0Common StockSEC:0002064538-26-000002:0
55,555 shares0Common StockSEC:0001040130-26-000034:0
55,555 shares0Common StockSEC:0001789515-26-000003:0
32,500 shares0Common StockSEC:0002035815-26-000004:0
32,500 sharesCommon StockSEC:0002035815-26-000002:0
26,057 shares0Common StockSEC:0001040130-26-000004:0
33,846 shares0Common StockSEC:0001040130-25-000088:0
33,846 shares0Common StockSEC:0002064538-25-000002:0
20,000 shares0Common StockSEC:0002035815-25-000011:0
33,846 shares0Common StockSEC:0002028705-25-000004:0
33,846 shares0Common StockSEC:0001789515-25-000003:0
34,866 shares0Common StockSEC:0001040130-25-000081:0
10,000 shares0Common StockSEC:0002035815-25-000009:0
40,000 shares0Common StockSEC:0002035815-25-000007:0
101,000 shares@ US$3.1735.2% of flowCommon Stock, par value $0.001SEC:0001903596-25-000404:0
Canonical exit: 11 Nov 2025 (T+90)
118,200 shares@ US$3.2166.1% of flowCommon Stock, par value $0.001SEC:0001903596-25-000383:0
Canonical exit: 30 Oct 2025 (T+90)
25,000 shares@ US$3.4973.8% of flowCommon StockSEC:0001213900-25-066628:0
Canonical exit: 19 Oct 2025 (T+90)
17,565 shares@ US$3.2328.7% of flowCommon Stock, par value $0.001SEC:0001903596-25-000348:0
Canonical exit: 16 Oct 2025 (T+90)
31,701 shares@ US$3.1570.8% of flowCommon Stock, par value $0.001SEC:0001903596-25-000346:0
Canonical exit: 15 Oct 2025 (T+90)
2,817 shares@ US$3.2221.7% of flowCommon Stock, par value $0.001SEC:0001903596-25-000330:0
Canonical exit: 30 Sept 2025 (T+90)
694 shares@ US$3.216.8% of flowCommon Stock, par value $0.001SEC:0001903596-25-000329:0
Canonical exit: 29 Sept 2025 (T+90)
25,000 shares@ US$3.9354.5% of flowCommon StockSEC:0001213900-25-051165:0
Canonical exit: 1 Sept 2025 (T+90)
25,000 shares@ US$3.864.7% of flowCommon StockSEC:0001213900-25-047347:0
Canonical exit: 19 Aug 2025 (T+90)
7,401 shares@ US$3.95100.0% of flowCommon Stock, par value $0.001SEC:0001903596-25-000291:0
Canonical exit: 18 Aug 2025 (T+90)
25 of 80 declarations
关于 Petmed Express INC
PetMed Express, Inc. (NASDAQ: PETS) 是一家美国专业动物健康零售商，以 PetMeds 品牌运营，近期也成为 PetCareRx 的母公司。该公司成立于 1996 年，总部位于美国佛罗里达州德尔雷比奇，更确切地说，它是一家直接面向消费者的宠物药房和在线供应商，而非传统的药品制造商。其商业模式侧重于为宠物主人提供便利、有竞争力的价格、快速配送和客户服务，销售渠道包括网站、免费电话热线和移动应用程序。其产品涵盖处方药和非处方药、宠物食品、补充剂、用品以及精选的兽医服务，主要面向狗、猫和马。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1040130/000104013023000033/pets-20230331.htm)) 从投资组合角度来看，PetMed Express 在更广泛的动物健康市场中运营着一个利基细分市场。该公司的产品种类历来广泛，其综合年度报告披露了大约 10,000 种宠物健康 SKU，而后续文件提及约 7,200 种商品，表明产品组合可能有所收紧。这种广度在竞争中仍然很重要，因为该公司不仅与其他宠物专业零售商竞争，还与综合电子商务平台、实体连锁店和兽医渠道竞争。其竞争优势来自于专业化、重复购买行为以及在宠物医疗领域长期建立的消费者品牌。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1040130/000104013025000072/pets-20250331.htm)) 最新的申报周期也凸显了运营和治理方面的整顿。PetMed Express 延迟提交了其 2025 财年 10-K 表格，此前纳斯达克于 2025 年 7 月发出了违规通知，原因是该报告未能按时提交。该公司 2025 财年年度报告还提及了审计委员会的调查以及与促销销售报销相关的重述，同时声明该调整对受影响期间的净收入没有影响。对于投资者而言，这些进展很重要，因为它们表明公司正处于转型期，更加强调报告纪律和执行质量。2025 财年文件披露，截至 2025 年 3 月 31 日，净销售额为 $227.0 million，净亏损为 $6.3 million，现金为 $54.7 million，且无债务。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1040130/000104013025000074/pets-2025331xex991.htm)) 2025 年 11 月，董事会将公司的股东权利计划延长至 2026 年 12 月 2 日，声明其认为股价未能反映公司的内在价值。此举，加上正在进行的运营重置，突显出公司正努力保护战略灵活性，同时重建投资者信心。总体而言，PetMed Express 仍然是一个在纳斯达克上市的美国健康和医药相关消费平台，拥有公认的品牌、专注的品类定位以及在数字宠物零售领域面临的激烈竞争。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1040130/000104013025000091/exhibit991pressrelease.htm))
